Biofrontera Inc.
NASDAQ: BFRIW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Hermann Luebbert
- Employees
- 92
- Headquarters
- Woburn, United States
- IPO year
- 2021
- Market cap
- $15.7M
- Website
- https://www.biofrontera-us.com
Loading BFRIW…
Loading profile data…Frequently asked questions about BFRIW
What does Biofrontera Inc. (BFRIW) do?
Biofrontera Inc. is a biopharmaceutical firm specializing in the commercialization of pharmaceutical solutions for skin-related ailments across the United States. Its product lineup features Ameluz, a prescription drug employed with the BF-RhodoLED lamp series for photodynamic therapy. This treatment is designed for both localized and broader ar...
Where does BFRIW trade?
Biofrontera Inc. (BFRIW) trades on the NASDAQ Capital Market.
What sector is BFRIW in?
Biofrontera Inc. (BFRIW) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Biofrontera Inc.?
Hermann Luebbert is the chief executive officer of Biofrontera Inc. (BFRIW).
Where is Biofrontera Inc. headquartered?
Biofrontera Inc. is headquartered in United States.
Does BFRIW pay a dividend?
Biofrontera Inc. (BFRIW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BFRIW go public?
Biofrontera Inc. (BFRIW) completed its initial public offering in 2021.